

Ajanta House, Charkop, Kandivli (West), Mumbai - 400 067 T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



15th September 2023

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Sub.: Movement in volume Security Code: 532331

This is with reference to the clarification sought by the exchange from the Company by disseminating the same in the Corporate Announcement section of the Company on 14th September 2023 relating to movement in volume of shares of the Company.

In this regard we hereby clarify that as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we have timely disclosed to the Exchanges all the information/events that have a bearing on the operations/performance of the Company and no such material information/event have remained to be disclosed.

Significant increase in the volume of securities of the Company is purely driven by market dynamics. We do not know whether there is any connection of this to one news article published by BQ Prime citing report of Motilal Oswal Financial Services to the investors today. All the information mentioned in the said news article about our company is already in the public domain. Link of the news article is:

https://www.bqprime.com/markets/ajanta-pharma-shares-at-all-time-high-after-august-sales-data.

The Company has always abided by and complied with all the disclosures and regulatory requirements and has meticulously followed all the Corporate Governance norms.

We hope the above clarifies the position.

Yours Faithfully,

Gaurang Shah

VP – Legal & Company Secretary

